Clozapine belongs to a group of drugs called atypical antipsychotics or second-generation antipsychotics medications. This medication is used to treat certain psychological disorders such as suicidal behavior associated with schizoaffective disorder. Clozapine market has high growth prospects owing to increasing awareness about metal health among patients. Moreover, with the increasing number of patients with psychological disorders, there has been a rise in demand for clozapine medications.This growth is primarily driven by Growing Awareness about Psychological Health and Increasing Prevalence of Psychological Disorders.
Globally, a noticeable market trend is evident Advancement in the Drug Discovery. Major Players, such as Novartis (Switzerland), Cambrex (United States), Arevipharma (Germany), Shouguang Fukang Pharmaceutical (China), Taizhou Xingming Pharmaceutical (China), Jinan Jinda (China), Yunyang Pharm (China), Wanbangde Pharm (China) and Hangzhou Longshine Bio-Tech (China) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.
“The US Food and Drug Administration (FDA) announced changes to its risk evaluation and mitigation strategy (REMS) for the antipsychotic drug clozapine, set to take effect on 28 February 2019. Under the latest modification to the clozapine REMS, FDA is making changes to who must be certified to participate in the program and restricting pharmacies from enrolling patients in the clozapine registry. As of 28 February 2019, FDA says that prescribers and pharmacies must be certified under the REMS or they will not be able to prescribe or dispense clozapine. Inpatient prescribers, on the other hand, do not need to be certified to prescribe clozapine to patients who are already enrolled in the registry. FDA is also allowing pharmacies to dispense clozapine to patients who do not have a current absolute neutrophil count (ANC) to ensure treatment is not disrupted.”
- Growing Awareness about Psychological Health
- Increasing Prevalence of Psychological Disorders
- Advancement in the Drug Discovery
- Stringent Government Regulations Regarding Clozapine Medications
Increasing Demand for the Treatment of Schizophrenia and Rising Demand from the Developing Economies
Side Effects such as Cardiac Toxicity, Weight Gain, Diabetes, And Others
AdvanceMarketAnalytics follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.
Customization of the Report:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase